Advair Diskus (Fluticasone / Salmeterol)

Advair Diskus is used to control asthma and chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis. It is an oral inhaler that contains two types of medication. Advair HFA contains fluticasone propionate, an inhaled corticosteroid medicine. Inhaled corticosteroids help to decrease inflammation in the lungs. ADVAIR is for patients 4 years and older. For patients 4 to 11 years old, ADVAIR 100/50 is for those who have asthma symptoms while on an inhaled corticosteroid.

Advair Diskus and certain other medicines may interact with each other. Tell your healthcare professional about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. Advair, a popular brand of asthma inhaler, has been linked to severe and potentially life-threatening complications in patients. The drug is designed to reduce airway constriction and inflammation in the lungs while easing symptoms, including wheezing, tightness of the chest, and shortness of breath. ADVAIR DISKUS should not be used for transferring patients from systemic corticosteroid therapy. Asthma: ADVAIR DISKUS is available in 3 strengths, ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50, containing 100, 250, and 500 mcg of fluticasone propionate, respectively, and 50 mcg of salmeterol per inhalation.

Advair has been associated with different side effects. Side effects of Advair can vary with dose. Advair HFA offers asthma patients who are unable to use dry-powder inhalers an alternative delivery system. Advair Diskus is generally not needed in patients whose asthma can be controlled easily with infrequent administration of short acting inhalers. Advair Diskus should not be used to treat acute episodes of asthma or COPD.

ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, and ADVAIR DISKUS 500/50 are specially designed plastic devices containing a double-foil blister strip of a powder formulation of fluticasone propionate and salmeterol xinafoate intended for oral inhalation only. Each blister on the double-foil strip within the device contains 100, 250, or 500 mcg of microfine fluticasone propionate and 72.5 mcg of microfine salmeterol xinafoate salt, equivalent to 50 mcg of salmeterol base, in 12.5 mg of formulation containing lactose (which contains milk proteins).